Literature DB >> 19619766

POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial.

Khalil Fattouch1, Francesco Guccione, Roberta Sampognaro, Gaetano Panzarella, Egle Corrado, Emiliano Navarra, Davide Calvaruso, Giovanni Ruvolo.   

Abstract

OBJECTIVE: Surgical management of moderate chronic ischemic mitral valve regurgitation is still debated. The aim of this study was to evaluate the effect of adding mitral valve repair to coronary artery bypass grafting on clinical outcomes and left ventricular remodeling in patients who underwent coronary artery bypass grafting alone versus coronary artery bypass grafting plus mitral valve repair in a randomized trial.
METHODS: Between February 2003 and May 2007, 102 patients were eligible for this study and were randomly assigned to one of 2 groups by means of card allocation: coronary artery bypass grafting plus mitral valve repair (CABG plus MVR group; 48 patients, 47%) or coronary artery bypass grafting alone (CABG group; 54 patients, 53%). The 2 groups were similar regarding demographics, perioperative clinical data, and outcomes. There were differences regarding cardiopulmonary bypass (P < .0001) and aortic crossclamp (P < .0001) times. Exercise tests were performed for all survivors to evaluate tolerance to exercise and variability on grade of mitral regurgitation and systolic pulmonary arterial pressure. The study was blinded for physicians and nurses involved in postoperative care and clinical follow-up. The mean follow-up was 32 +/- 18 months.
RESULTS: Overall in-hospital mortality was 3% (3 patients). One (1.8%) patient died in the CABG group, and 2 (4.1%) patients died in the CABG plus MVR group. Survival rates +/- standard error at 5 years for patients in the CABG and CABG plus MVR groups were 88.8% +/- 3.2% and 93.7% +/- 3.1%, respectively. A significant difference was found between the 2 groups with regard to mean New York Heart Association class (P < .0001), left ventricular end-diastolic diameter (P < .01), left ventricular end-systolic diameter (P < .01), pulmonary arterial pressure (P < .0001), and left atrial size (P < .01). At follow-up, coronary artery bypass grafting alone was able to reduce mitral regurgitation grade in 40% of patients, whereas in the remaining patients mitral regurgitation grade remained stable or worsened. In the CABG group, among the 17 patients with mild mitral regurgitation and 12 patients with moderate mitral regurgitation at rest, 7 (40%) and 9 (75%) patients, respectively, had worsening in mitral regurgitation grade and pulmonary artery pressure during exercise.
CONCLUSIONS: The efficacy of adding mitral valve repair to coronary artery bypass grafting is well demonstrated by the improvement of New York Heart Association functional class and percentage of left ventricular ejection fraction and by the decrease of mitral regurgitation grade, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, pulmonary artery pressure, and left atrial size. Moreover, coronary artery bypass grafting alone left more patients with heart failure symptoms at rest and during exercise. Combined coronary artery bypass grafting and mitral valve repair have no effect on survival at short-term follow-up, and the trends that are evident will likely become more significant with time.

Entities:  

Mesh:

Year:  2009        PMID: 19619766     DOI: 10.1016/j.jtcvs.2008.11.010

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  54 in total

Review 1.  Surgical approach to mitral regurgitation in chronic heart failure: when is it an option?

Authors:  Juan A Crestanello
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 2.  Therapeutic decision-making for patients with fluctuating mitral regurgitation.

Authors:  Patrizio Lancellotti; Khalil Fattouch; Giovanni La Canna
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

3.  Surgical options for the management of ischemic cardiomyopathy.

Authors:  Robert Michler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

Review 4.  Ischemic and functional mitral regurgitation in heart failure: natural history and treatment.

Authors:  Mina M Benjamin; Robert L Smith; Paul A Grayburn
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

Review 5.  Benefits of submitral procedures for ischemic mitral regurgitation.

Authors:  Satoru Wakasa; Yoshiro Matsui
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-07-15

6.  Off-pump mitral valve repair: primary result of treating moderate ischemic mitral regurgitation during off-pump coronary artery bypass grafting.

Authors:  Jingxing Li; Chengxiong Gu
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

7.  Insights into functional mitral regurgitation using the average pixel intensity method.

Authors:  Victor Kamoen; Milad El Haddad; Tine De Backer; Marc De Buyzere; Frank Timmermans
Journal:  Int J Cardiovasc Imaging       Date:  2018-12-03       Impact factor: 2.357

8.  Ischemic Mitral Regurgitation: Current Understanding and Surgical Options.

Authors:  Alexander Angelo Brescia; Tessa Maria Fontana Watt; Steven Frederic Bolling
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-04-06

Review 9.  The Evolving Role of Percutaneous Mitral Valve Repair.

Authors:  Merrill H Stewart; J Stephen Jenkins
Journal:  Ochsner J       Date:  2016

10.  [Mitral regurgitation in heart failure. Surgical therapy].

Authors:  H Aubin; H Kamiya; A Lichtenberg
Journal:  Herz       Date:  2013-03       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.